#COVI19

Dr Nicole E Basta

IDEpiPhD

Very promising news that the Pfizer/BioNtech #COVID19 #vaccine candidate BNT162b2 demonstrated more than 90% efficacy in the first phase 3 interim analysis (after 94 events).https://biontechse.gcs-web.com/news-releases/news-release-details/

Seb Allaman

AllamanSeb

1. NZZ says that's ICU aren't full in Switzerland, and that people spread a fake rumor... They say they have more serious sources. Let me show you that the inverse

Athena Akrami

AthenaAkrami

And here is the preprint: "Characterizing Long COVID in an International Cohort: 7 Months of Symptoms and Their Impact" Special thanks to thousands of you who participated in our study

By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.